1) Andrews DW et al : Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases : phase III results of the RTOG 9508 randomised trial. Lancet 363 : 1665-72, 2004
2) Aoyama H et al : Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases : a randomized controlled trial. JAMA 295 : 2483-91, 2006
3) Yamamoto M et al : Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901) : a multi-institutional prospective observational study. Lancet Oncol 15 (4) : 387-95, 2014
4) Chang EL et al : Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus wholebrain irradiation : a randomised controlled trial. Lancet Oncol 10 : 1037-44, 2019
5) Brown P D et al : Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases : A Randomized Clinical Trial, JAMA 316 (4) : 401-409, 2016
6) Rusthoven CG et al : Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases : The FIRE-SCLC Cohort Study. JAMA oncology 6 (7) ; 1028-1037, 2020
7) NCCN Guidelines Small Cell Lung Cancer Version 2. Principles of Radiation Therapy, Brain Metastases SCLF 4-5, 2021
8) Lucia F et al : Inhomogeneous tumor dose distribution provides better local control than homogeneous distribution in stereotactic radiotherapy for brain metastases. Radiotherapy and Oncology 130 : 132-138, 2019
9) Christopher Abraham MD a et al : Internal dose escalation is associated with increased local control for non-small cell lung cancer (NSCLC) brain metastases treated with stereotactic radiosurgery (SRS) Advances in Radiation Oncology 3, 146-153, 2018
10) Nataf F et al : Radiosurgery with or without a 2-mm margin for 93 single brain metastases, Int. J. Radiation Oncology Biol. Phys., Vol. 70, No. 3, pp. 766-772, 2008
11) Chin LS et al : Radiation necrosis following gamma knife surgery : a case-controlled comparison of treatment parameters and long-term clinical follow up. stereotactic radiosurgery. Neurosurgery 94 (6) : 899-904, 2001
12) C Faivre-Finn et al : Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial Journal of Thoracic Oncology, Available online 19 January In Press, 2021
13) A Carretero-Gonzalez et al : Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors : a meta-analysis of randomized clinical trials Oncotarget Vol. 9, (No. 9), pp : 8706-8715, 2018
14) T Abe et al : Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemo-radiotherapy alone, Thoracic Cancer 12 : 245-250, 2021
15) Tom L et al : Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases, Clinical Lung Cancer, in Press, Available online 18 Nov 2020
16) Bradley JD et al : Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617) : a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16 : 187-99, 2015
17) Machtay M et al : Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation : an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 82 : 425-34, 2012
18) van Diessen JN et al : Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy. Radiother Oncol 118 (3) : 447-52, 2016
19) Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial (JAMA Oncol. 2019 Jul 11. doi : 10.1001/jamaoncol. 2019. 1478
20) YJ Kim et al : Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies, Radiation Oncology volume 13, Article number : 127, 2018
21) Paz-Ares L et al : Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann. Oncol 31, 798-806, 2020
22) H Menon et al : Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy, Journal for Immuno Therapy of Cancer 7 : 237, 2019
23) JE Schoenhals et al : Uncovering the immune tumor micro-environment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Transl Lung Cancer Res 6 (2) : 148-158, 2017
24) Timmerman et al : Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer. JAMA Oncol 4, 1287-1288, 2018
25) X Mielgo-Rubio et al : Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer : Emerging Evidence and the Role of Biomarkers. Cancers 12, 3459, 2020